We are conducting ongoing clinical trials against hepatocellular carcinoma to evaluate the safety and efficacy of our TCR-T cells.
Hepatocellular carcinoma (HCC), the most frequent subtype of liver cancer, is the third leading cause of cancer death in the world. About 50 to 80% of HCC cases are caused by Hepatitis B virus (HBV) infection, a major health problem that afflicts 270 million people worldwide.
Our lead product, LioCyx-M, an autologous T-cell product transfected with mRNA encoding HBV antigen-specific TCR, has been used clinically for the treatment of HBV-related liver cancer and recurrent HBV-related liver cancer post liver transplant.
Lion TCR is committed to providing safe and effective investigational therapies to patients in need through clinical studies.
Contact us at clinicaltrials@liontcr.com for more information.
Expanded Access Policy
There may, however, be circumstances when patients who are seriously ill have exhausted all available treatment and are not be eligible for our clinical trials.
In those cases, patients may be eligible for treatment with an investigational therapy through programs referred to as ‘Expanded Access Programs’ (EAPs) or ‘compassionate use’.
For our EAP, please click here for more information.
We aspire to be the world’s leader in the field of TCR-T therapy through the technological advancement and development of adoptiveT cell therapy products for viral related cancers and chronic hepatitis infection.
Status: Upcoming
Study Type: Multi-center, multi-arm, open-label Phase 1b/2 study
Objective: To determine safety and efficacy of LioCyx-M as a monotherapy and as a combinational therapy with existing standard of care drug sorafenib or lenvatinib in primary HCC patients
Status: Upcoming
Study Type: Single center, single arm, open-label Phase 1 study
Objective: To determine the safety of LioCyx-M and to analyze the changes in tumor microenvironment caused by LioCyx-M in patients with HBV-related HCC who are not amenable to/failed conventional treatment
Status: Upcoming
Study Type: Single center, single arm, open-label Phase 1 study
Objective: To assess the safety and efficacy of LioCyx-M to prevent HCC recurrence post liver transplantation for patients with HBV-related HCC after liver transplantation
Status: Completed (SITC 2020)
Study Type: Single center, single arm, open-labelPhase 1 study
Objective: To assess the safety and efficacy of LioCyx-M for patients with recurrent HBV-related HCC post liver transplantation
Status: Completed (SITC 2020, EASL DILC 2021)
Study Type: Single center, single arm, open-label Phase 1 study
Objective: To assess the safety and efficacy of LioCyx-M for patients with advanced primary HBV-HCC
